Capital Investment in Alvotech Holdings and Exclusive Biosimilar Partnership
First written in FY2018. 3 of 7 entries say "Advanced", first in FY2019-Q1. Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022AdvancedAnnual report
「For biosimilars, we are jointly developing 6 products with Alvotech, preparing an application for approval for 1 of them, and discussing 1 additional product.」
Development based on the equity investment and exclusive partnership with Alvotech has expanded to 6 drugs, with preparations under way for 1 marketing authorization application and discussions under way on 1 formulation. - FY2021RestatedAnnual report
「For biosimilars, we are jointly developing 5 products with Alvotech and discussing 2 additional products.」
Continues biosimilar development based on the exclusive partnership and equity investment with Alvotech, with 5 drugs under joint development and discussions under way on 2 formulations. - FY2020AdvancedAnnual report
「For biosimilars, we have begun joint development with Alvotech of 5 products.」
Describes progress under the exclusive partnership and equity investment with Alvotech, namely the start of joint development of 5 drugs, giving concrete form to the partnership covering multiple products. - FY2019-Q3RestatedAnnual report
「On 16 December 2018, we agreed with Alvotech hf, a member of the Alvogen Group, on an exclusive partnership for the commercialization in Japan of multiple biosimilars and decided to acquire an equity interest in Alvotech HD in order to further deepen the relationship between the two companies.」
Describes the same content as in the previous quarter regarding the exclusive biosimilar partnership with Alvotech hf and the equity investment in Alvotech HD. - FY2019-Q2RestatedAnnual report
「On 16 December 2018, we agreed with Alvotech hf, a member of the Alvogen Group, on an exclusive partnership for the commercialization in Japan of multiple biosimilars and decided to acquire an equity interest in Alvotech HD in order to further deepen the relationship between the two companies.」
Describes the same content as in the previous quarter regarding the exclusive biosimilar partnership with Alvotech hf and the equity investment in Alvotech HD. - FY2019-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 16 December 2018, we resolved to invest US$50 million in Alvotech Holdings, headquartered in Luxembourg, hereinafter “Alvotech HD,” and have implemented the investment as follows.」
Discloses that 281,400 shares were acquired on 17 January 2019 in connection with the US$50 million investment in Alvotech HD, resulting in a 4.22% voting interest. In addition to the exclusive biosimilar partnership, the equity investment has moved into the implementation stage. - FY2018First statedAnnual report
「At a meeting of the Board of Directors held on 16 December 2018, we resolved to invest US$50 million in Alvotech Holdings, headquartered in Luxembourg, hereinafter “Alvotech HD,” and entered into a share transfer agreement on the same day. We had agreed with Alvotech hf on an exclusive partnership for the commercialization in Japan of multiple biosimilar products. To further deepen the relationship between the two companies, we have now agreed to make an equity investment in Alvotech HD. We may also second 1 director to Alvotech HD, enabling us to obtain timely updates on the progress of research and development.」
As a subsequent event, describes the specific details of the equity investment: a US$50 million investment based on the Board of Directors’ resolution of 16 December 2018, the scheduled acquisition of shares on 15 January 2019, a 4.22% voting interest, and the ability to second 1 director.